Victory Capital Management Inc. Has $13.48 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Victory Capital Management Inc. grew its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 795.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 369,367 shares of the company's stock after acquiring an additional 328,127 shares during the quarter. Victory Capital Management Inc. owned about 0.59% of SpringWorks Therapeutics worth $13,482,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of SWTX. China Universal Asset Management Co. Ltd. increased its stake in SpringWorks Therapeutics by 96.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,612 shares of the company's stock worth $37,000 after buying an additional 792 shares during the period. Headlands Technologies LLC purchased a new stake in SpringWorks Therapeutics during the 4th quarter worth approximately $74,000. Strs Ohio acquired a new position in shares of SpringWorks Therapeutics in the 4th quarter valued at approximately $102,000. SG Americas Securities LLC purchased a new position in shares of SpringWorks Therapeutics during the 4th quarter valued at approximately $157,000. Finally, Exchange Traded Concepts LLC grew its position in shares of SpringWorks Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 5,323 shares of the company's stock worth $194,000 after buying an additional 1,350 shares in the last quarter.

SpringWorks Therapeutics Stock Performance

Shares of NASDAQ:SWTX traded down $2.06 during trading on Friday, reaching $40.89. The company had a trading volume of 606,631 shares, compared to its average volume of 989,570. SpringWorks Therapeutics, Inc. has a twelve month low of $18.00 and a twelve month high of $53.92. The firm has a market capitalization of $3.03 billion, a PE ratio of -7.96 and a beta of 0.84. The firm's fifty day moving average is $46.58 and its 200 day moving average is $39.39.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.01). The business had revenue of $21.00 million for the quarter, compared to analysts' expectations of $12.07 million. The business's revenue was up 2000.0% compared to the same quarter last year. During the same quarter last year, the business posted ($1.18) EPS. Equities analysts predict that SpringWorks Therapeutics, Inc. will post -4.8 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Daniel Pichl sold 15,000 shares of the company's stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $50.10, for a total value of $751,500.00. Following the completion of the sale, the insider now owns 45,212 shares in the company, valued at approximately $2,265,121.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 7.61% of the company's stock.

Analyst Ratings Changes

Several research analysts have weighed in on SWTX shares. Wedbush reissued an "outperform" rating and set a $75.00 price objective (up from $70.00) on shares of SpringWorks Therapeutics in a report on Thursday, May 2nd. HC Wainwright reaffirmed a "buy" rating and issued a $74.00 price target on shares of SpringWorks Therapeutics in a report on Monday, May 6th. Barclays increased their target price on SpringWorks Therapeutics from $47.00 to $63.00 and gave the stock an "overweight" rating in a research report on Thursday, February 29th. Guggenheim started coverage on shares of SpringWorks Therapeutics in a research report on Monday, February 5th. They set a "buy" rating and a $75.00 price target for the company. Finally, JPMorgan Chase & Co. boosted their target price on shares of SpringWorks Therapeutics from $73.00 to $74.00 and gave the company an "overweight" rating in a research note on Wednesday, March 6th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $68.83.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.